Enanta Pharmaceuticals Inc
ENTA
查看详细走势图
13.510USD
+0.540+4.16%
收盘 02/06, 16:00（美东）报价延迟15分钟
288.94M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.16%
5天
+4.73%
1月
-0.52%
6月
+89.75%
今年开始到现在
-14.33%
1年
+172.38%
查看详细走势图
TradingKey Enanta Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Enanta Pharmaceuticals Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名68/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价19.12。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Enanta Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Enanta Pharmaceuticals Inc亮点
亮点风险
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
业绩增长期
公司处于发展阶段，最新年度总收入65.32M美元
估值低估
公司最新PE估值-3.52，处于3年历史低位
机构加仓
最新机构持股19.84M股，环比增加6.96%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值1.90K
分析师目标
根据
8
位分析师
买入
评级
19.125
目标均价
+47.46%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Enanta Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Enanta Pharmaceuticals Inc简介
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
公司代码ENTA
公司Enanta Pharmaceuticals Inc
CEOLuly (Jay R)
网址https://www.enanta.com/
相关品种
